Seroprevalence of Covid-19 in the Staff of the University Hospitals of Strasbourg
SeroPrevHUS
Seroprevalence of SARS-CoV 2 in the Staff of the University Hospitals of Strasbourg
1 other identifier
observational
5,694
1 country
1
Brief Summary
The Grand Est region is one of the most affected regions in France during the first wave of the COVID-19 epidemic. A significant increase in the number of patients hospitalized for SARS-CoV 2 infection at the University Hospitals of Strasbourg (HUS) led to a sudden saturation of their capacities. Hospital workers appear to be a population at particular risk for this new infectious agent. The percentage of hospital workers who have been in contact with the virus or have contracted COVID-19 is unknown. The objective of this work is to determine the prevalence of SARS-CoV-2 positive serologies among hospital staff screened from June 22, 2020 to November 1, 2020 following a screening campaign offering serological testing to all volunteer HUS professionals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 24, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 24, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 24, 2022
CompletedFirst Submitted
Initial submission to the registry
December 13, 2022
CompletedFirst Posted
Study publicly available on registry
December 15, 2022
CompletedDecember 11, 2023
December 1, 2023
10 months
December 13, 2022
December 8, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To determine the positive seroprevalence of SARS-CoV-2 among hospital staff screened from June 22, 2020 to November 1, 2020
Seroprevalence will be estimated by calculating the rate of seropositive subjects with its 95% confidence interval
Files analysed retrospectively from June 22, 2020 to November 1, 2020 will be examined
Eligibility Criteria
Hospital staff practicing at HUS who performed SARS-CoV 2 serology in the period from 06/22/2020 to 11/1/2020
You may qualify if:
- Adult subject (≥ 18 years of age)
- Hospital staff practicing at HUS who performed SARS-CoV 2 serology in the period from 06/22/2020 to 11/1/2020
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Service Laboratoire de Virologie - PTM - CHU de Strasbourg - France
Strasbourg, 67091, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 13, 2022
First Posted
December 15, 2022
Study Start
June 24, 2021
Primary Completion
April 24, 2022
Study Completion
June 24, 2022
Last Updated
December 11, 2023
Record last verified: 2023-12